Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive Allosteric Modulator in Development for the Treatment of Schizophrenia

CVL-231 is a positive allosteric modulator (PAM) designed to selectively target the M4 muscarinic receptor. M4 muscarinic receptors have been shown to influence the levels of acetylcholine and dopamine, key neurotransmitters in the brain that are known to be dysregulated in diseases like schizophrenia


Awesome, I have high hopes for M4 and M1 drugs.


Is it for negative symptoms…!!

There’s not much published on it. In the 1b study they are mostly looking at safety and tolerability.

Other M4 drugs have been described as targeting positive and cognitive symptoms with limited side effects and better safety. But none has yet made it to late stage trials.

1 Like